Knott David M Has Lifted By $366,300 Its Stemline Therapeutics (STML) Holding; Shorts at LDK SOLAR COMPANY LTD (LDKYQ) Raised By 8.57%

January 15, 2018 - By Linda Rogers

LDK SOLAR COMPANY LTD (OTCMKTS:LDKYQ) had an increase of 8.57% in short interest. LDKYQ’s SI was 380,200 shares in January as released by FINRA. Its up 8.57% from 350,200 shares previously. With 261,000 avg volume, 2 days are for LDK SOLAR COMPANY LTD (OTCMKTS:LDKYQ)’s short sellers to cover LDKYQ’s short positions. The stock increased 4.71% or $0.0004 during the last trading session, reaching $0.0089. About shares traded. LDK Solar Co., Ltd. (OTCMKTS:LDKYQ) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Knott David M increased Stemline Therapeutics Inc. (STML) stake by 79.87% reported in 2017Q3 SEC filing. Knott David M acquired 33,300 shares as Stemline Therapeutics Inc. (STML)’s stock rose 22.79%. The Knott David M holds 74,992 shares with $832,000 value, up from 41,692 last quarter. Stemline Therapeutics Inc. now has $356.55M valuation. The stock increased 1.81% or $0.25 during the last trading session, reaching $14.1. About 100,595 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since January 15, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

LDK Solar Co., Ltd., through its subsidiaries, designs, develops, makes, and markets photovoltaic products in the PeopleÂ’s Republic of China, Europe, the Asia Pacific, and North America. The company has market cap of $2.78 million. The firm operates through two divisions, Polysilicon and Other PV Products. It currently has negative earnings. It produces and sells solar-grade and electronic-grade polysilicon.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It is positive, as 6 investors sold STML shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported. Baldwin Brothers Inc Ma reported 0.01% stake. California Pub Employees Retirement Sys reported 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Moreover, Citigroup has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 70 shares. Goldman Sachs Gp Inc Inc stated it has 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Fmr Lc has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Schwab Charles Management owns 40,200 shares or 0% of their US portfolio. Bank & Trust Of America De accumulated 4,276 shares. Pura Vida Invs Limited holds 60,000 shares or 0.33% of its portfolio. Metropolitan Life Insur Ny owns 15,763 shares. Aqr Capital Management Limited Liability Corporation has 19,074 shares for 0% of their portfolio. Balyasny Asset Management Ltd Liability Com owns 17,400 shares or 0% of their US portfolio. Farallon Cap Mgmt Ltd Liability Corp holds 0.12% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 1.19M shares. One Trading LP has 1,309 shares for 0% of their portfolio. Lyon Street Ltd Liability stated it has 2.32% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Blackrock Inc reported 0% stake.

Knott David M decreased Pfizer Inc. (NYSE:PFE) stake by 57,000 shares to 978,676 valued at $34.94M in 2017Q3. It also reduced Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stake by 200,000 shares and now owns 798,100 shares. Abbvie Inc. (NYSE:ABBV) was reduced too.

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 12 analyst reports since November 10, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 14 by Cowen & Co. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Outperform” rating given on Monday, February 6 by Wedbush. The firm earned “Buy” rating on Thursday, December 14 by H.C. Wainwright. The firm has “Buy” rating by Jefferies given on Monday, June 26. The firm has “Buy” rating given on Friday, June 23 by Cowen & Co. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Monday, June 26 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 1. The rating was maintained by H.C. Wainwright on Friday, November 10 with “Buy”. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) rating on Wednesday, August 9. H.C. Wainwright has “Buy” rating and $3400 target.

Since December 15, 2017, it had 0 buys, and 2 insider sales for $365,519 activity. Hoberman Kenneth sold 11,983 shares worth $169,942.